

1 **Cluster analysis of epidemiological characteristic features of confirmed cases**
2 **with the novel coronavirus (COVID-19) outside China: a descriptive study**

3
4 *Minh-Duc Nguyen-Tran^{1,2,⊕}, Ali Ahmed-Fouad Abozaid^{2,3,⊕}, Luu Lam Thang Tai^{2,4,⊕}, Le*
5 *Huu Nhat Minh^{1,2,⊕}, Quang-Loc Le^{1,2}, Hoang-Dung Nguyen^{1,2}, Khanh-Linh Dao^{2,5}, Huu-*
6 *Hoai Le^{1,2}, Nguyen Tien Huy^{6,*}*

7
8 *¹Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh*
9 *City 700000, Vietnam*

10 *²Online Research Club (<http://www.onlineresearchclub.org/>), Nagasaki, Japan*

11 *³Faculty of Medicine, Ain Shams University, Cairo 11843, Egypt*

12 *⁴Department of Emergency, City children's hospital, Ho Chi Minh City, 700000, Vietnam*

13 *⁵Faculty of Medicine, Haiphong University of Medicine and Pharmacy, Hai Phong City ,*
14 *Vietnam.*

15 *⁶Department of Clinical Product Development, Institute of Tropical Medicine (NEKKEN), School*
16 *of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan.*

17 *⊕Authors equally contributed the work.*

18 **Correspondence to: Nguyen Tien Huy, Institute of Tropical Medicine (NEKKEN), School of*
19 *Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan*

20 *(E-Mail: tienhuy@nagasaki-u.ac.jp)*

21

22

23

24

25 **Emails:**

26 MDNT: minhduc1298@gmail.com (ORCID: [0000-0002-9333-7539](https://orcid.org/0000-0002-9333-7539))

27 AAFA: aliamedfouad@gmail.com (ORCID: [0000-0001-6308-537X](https://orcid.org/0000-0001-6308-537X))

28 LLTT: luulamthangtai0105@gmail.com (ORCID: [0000-0003-1062-2463](https://orcid.org/0000-0003-1062-2463))

29 LHNM: lehuunhatminh.md@ump.edu.vn (ORCID: [0000-0002-7728-1539](https://orcid.org/0000-0002-7728-1539))

30 QLL: lequangloc.md@gmail.com (ORCID: [0000-0001-6363-9862](https://orcid.org/0000-0001-6363-9862))

31 HDN: nguyenhoangdung1501@gmail.com (ORCID: [0000-0002-9815-6112](https://orcid.org/0000-0002-9815-6112))

32 KLD: daolinh2024@gmail.com (ORCID: [0000-0002-4623-0245](https://orcid.org/0000-0002-4623-0245))

33 HHL: huhuhoai.md@gmail.com (ORCID: [0000-0002-2018-1713](https://orcid.org/0000-0002-2018-1713))

34 NTH: tienhuy@nagasaki-u.ac.jp (ORCID: [0000-0002-9543-9440](https://orcid.org/0000-0002-9543-9440))

35

36

37

38

39

40

41

42

43

44

45

46

47

48 **ABSTRACT**

49 **Background:** Novel coronavirus COVID-19 has caused significant global outbreaks outside
50 China. Many countries have closed their borders with China and performed obligate protective
51 procedures, however, this disease was still rising worldwide. In this report, we aim to identify
52 transmission patterns from China to other countries, along with describing the disease control
53 situation of countries.

54 **Methods:** We retrospectively collected information about infected cases with COVID-19 from
55 WHO situation reports, official notification websites of health ministries and reliable local
56 newspapers from each country. Descriptive and cluster analysis was performed to describe the
57 transmission characteristics while the logistic regression test was used to estimate the risk factors
58 for the occurrence of an infected individual with an unknown source.

59 **Results:** A total of 446 infected cases were recorded from 24 countries outside China until 12
60 February 2020, with the number of reported infected cases were doubled every 3.08 ± 0.35 days
61 (range from 2.6 to 3.9). Besides the spread from China, the transmission was originated from
62 sub-endemic countries (Japan, Thailand, Singapore, Malaysia, France, German). Out of 6
63 countries got occurrence of an infected individual with unknown source and possible potential
64 factors contributed to this occurrence was a time of epidemic circulating, number of patients and
65 number of clusters when the occurrence still has not happened, and notably, the unreported
66 situation of Chinese tourists' information.

67 **Conclusions:** The situational reports of each country about COVID-19 should be more detailed
68 mentioning the transmissions routes with keeping contact tracing of the unknown cases to
69 increase the control of this disease.

70

71 **Keywords:**

72 COVID-19, SARS-CoV-2, novel coronavirus, outbreak, cluster, transmission.

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97 **BACKGROUND**

98
99 Novel coronavirus is a new strain of the previously discovered Coronaviridae family, a member
100 of RNA viruses of the order Nidovirales which own spiky projections on their outer surfaces that
101 resemble the shape of a crown, or "corona" in Latin¹. They are zoonotic viruses infecting mainly
102 birds and mammals, in addition to humans. Human coronavirus infections are mostly mild,
103 however, in the past two decades, two beta-coronaviruses; the Severe Acute Respiratory
104 Syndrome Coronavirus (SARS-CoV), and the Middle East Respiratory Syndrome Coronavirus
105 (MERS-CoV) have infected more than 10,000 patients over a potentially short period of time¹⁻⁵.
106 With mortality rates of 10% for SARS-CoV and 37% for MERS-CoV, respectively, they are one
107 of the most devastating epidemics all over the world⁶.

108 On December 31, 2019, an outbreak of severe acute pneumonia with unknown etiology occurred
109 in Wuhan with people who attended a wild animal and seafood market in China. China
110 discovered at this time a new strain of coronavirus resembles SARS-CoV and has informed the
111 world health organization (WHO) about this new catastrophe and new countries have taken
112 obligate procedures to prevent the virus from spread abroad^{7,8}. However, Multiple countries of
113 almost all continents including the USA, Vietnam, Germany and Australia have reported
114 confirmed cases of SARS-CoV-2⁹. COVID-19 possesses an exceptional ability of transmission
115 and no specific treatment for it has been reported. Infected patients are managed with supportive
116 care, but antiviral medications and combination treatment have been reported to be used¹⁰. The
117 clinical symptoms of SARS-CoV-2 have been reported as fever, dyspnea, cough, abdominal
118 distress, and in severe cases, it could lead to complications such as acute respiratory distress
119 syndrome (ARDS), pulmonary edema and multiorgan failure¹¹.
120 Furthermore, efforts in measures implemented so far have been directed towards preventing and

121 containing the risk of spread beyond such local clusters to prevent extensive community spread.
122 Recently, an asymptomatic transmission has been reported in many countries including Germany,
123 South Korea, China¹²⁻¹⁴; WHO has reported that the transmission occurred easily by face to face
124 through coughing, sneezing, contact with secretions of infected people like nasal and oral
125 droplets, tears or substantially by fecal-oral route¹⁵. The basic reproduction rate of COVID-19
126 estimated at 3.28 representing the highly contagious transmissibility of this disease putting us on
127 a great challenge for containment this largely infectious disease outside China¹⁶. In this report,
128 we aimed to investigate the epidemiological importance of clustering the COVID-19 confirmed
129 cases outside China to increase the awareness of these countries to develop more appropriate
130 surveillance system ways to limit the spread of SARS-CoV-2 and contact trace of their unknown
131 cases.

132

133 **METHODS**

134 *Data collection and search strategy*

135 We initially obtained data from a manual search of clinically confirmed COVID-19 through
136 ProMED, WHO, CDC, ministries of health of different countries press releases, journal case
137 reports like Lancet and New England Journal of Medicine (NEJM) and local news. We used
138 since then many search keywords to get these data including ‘novel coronavirus’, ‘COVID-19’,
139 ‘SARS-CoV-2’, ‘2019-nCoV’, ‘cluster’, ‘transmission’ and ‘contact tracing’ ‘Wuhan’ and others.
140 The data acquired have been sorted according to demographic characteristics such as age, sex,
141 country, history of contact or travel, announcement date and the transmission clusters. February
142 12, 2020 was the last date we have done these searches.

143 *Sources reliability*

144 We have measured the reliability of our sources using The Journal of the American Medical
145 Association (JAMA) four benchmarks published in 1997. The four criteria involved the
146 authorship (the information of authors or writers and their affiliation should be provided),
147 attribution (the sources have to list their references prominently), disclosure (ownership, funding
148 source, advertisement and conflict of interests should be obvious for readers) and currency (the
149 date of publishing and updating contents should be posted)¹⁷.

150 *Ethical condition*

151 All data have been acquired from online sources and governments' websites without any direct
152 contact data from patients.

153 *Definition of epidemiology of infectious clusters and doubling time*

154 We defined the transmission clusters epidemiologically into four main types, A, B, C, and D,
155 based on the infectious source and risk of an outbreak. A cluster was classified into group A if the
156 primary pathogen had a history of traveling to China or have been in contact with foreigners
157 abroad outside countries, who were later confirmed SARS-CoV-2-infection. Because it was
158 impossible to determine who exactly spread the disease in the case of an infected group returned
159 from China, each of the patients in the group would be considered as an independent primary
160 pathogen and established an independent cluster. Group B involved clusters that patients without
161 traveling to China but got local contact with Chinese tourists. Due to the information of Chinese
162 tourists was not disclosed and such tourists were not reported as infected cases, we considered
163 clusters in group B to be at higher risk of an outbreak than group A. Groups C and D, at more
164 risk, included clusters where the source of infection could not be identified. While patients in a
165 cluster C were involved with a specific area, such as a church, a conference, etc., information of
166 patients in clusters D remained completely unknown.

167 The doubling time in our study is defined as the time required for the number of reported cases to
168 double. It was calculated based on the formula: $N = N_0 \cdot 2^{\frac{t}{T}}$. Because we only could record the
169 date of diagnosis (not the date of expose), the value hence only partially reflected the rate of
170 disease transmission.

171 *Statistical analysis*

172 Descriptive demographic and cluster analysis have been conducted inclusively for this dataset.
173 The missing data have been considered as unreported due to some governments didn't reveal
174 these data to protect the personality of their patients. Logistic regression then was performed to
175 determine relationships between potential factors and the occurrence of an infected with
176 unknown source, with the significant value chosen was < 0.05 .

177 178 **RESULTS**

179 180 *Demographic characteristic of infected patients*

181 We have identified 446 cases from 24 countries confirmed with COVID-19 infection outside
182 China. The median (IQR) number of reported cases doubling time was 3.08 ± 0.35 (range from
183 2.6 to 3.9) days and recorded the highest increase of reports ($n = 113$) between 10-Feb and 11-
184 Feb 2020, mostly from cases of Diamond Princess (**Figure 1**)¹⁸. Concisely, the most affected
185 country with the biggest number of infected patients was Singapore with a total number of 50
186 since the beginning of the outbreak up to February 12, 2020 (**Table 1**)¹⁹. The first case outside
187 China was reported in Thailand on January 13, 2020²⁰. Further details of the sequences of these
188 cases in each country are presented in the *Supplementary document*.

189 Approximately, 57% of the COVID-19 infected patients were males compared to 43% female
190 patients. The median (IQR) age was 42 (32-56), and the youngest infected patient was a three-
191 month old child from Vietnam²¹. All patients survived up to this date (February 12, 2020), and

192 some were even discharged from the hospital except for one case who died on February 2, 2020.

193 The patient was a 44-year old male passenger coming from Wuhan to Philippines²². Other

194 demographic characteristics of the included patients were presented in **Table 2**.

195 *Transmission outside China*

196 A total of 214 transmission clusters from 446 patients were determined. There were 178 clusters

197 (83.2%) that were involved with China and 12 clusters (5.6%) were spread from other sub-

198 endemic countries (Japan, Thailand, Singapore, Malaysia, France, German). Spain was the only

199 country in which the spread of COVID-19 from China was completely indirect, and Korea

200 represented the most counties have indirect transmission. More details of these transmissions

201 were shown in **Figure 2**.

202 **Table 3** showed a summary of the size and the type of clusters. The biggest cluster recognized

203 was the Diamond Cruise ship, with a total of 175 infected patients^{18,24-26}, followed by the cluster

204 in Germany (13 patients), Singapore (9 patients), France, Viet Nam, UK, Korea (6 patients)

205 ^{19,21,27}. Notably, Results also have shown that the number of clusters of Group A, B, C and D was

206 respectively 182 (85.0%), 9 (4.2%), 10 (4.7%), 13 (6.1%). When approaching group, A, B, we

207 found that 168 non-transmissible clusters (1-patient cluster), 18 clusters confirmed the local

208 transmission between primary pathogen and local people, and 5 clusters recognized the

209 transmission between local people.

210 At the national level, out of 24 countries infected with COVID-19, the occurrence of an infected

211 individual with unknown source happened in 6 countries (Australia, Germany, Japan, Singapore,

212 Thailand, UAE). Summarily, there were 13 countries that local human-human transmission

213 began, with the number of local transmission (F2 and F3) range from 5.6% in Malaysia to 55.6%

214 in UK from identified primary pathogen (F1). Other information has been summarized in **Table**

215 4.

216 *Occurrence of an infected individual with unknown source*

217 **Table 5** showed the associated factor with the occurrence of an infected individual with
218 unknown source. Time period from the first case reported until Feb 12 was related with
219 increasing of the risk ($p = 0.044$) (OR: 0.76) [95% CI: 0.58-0.99]. Notably, countries which was
220 unreported information of Chinese tourists was associated with highly significant risk of
221 occurrence event ($p = 0.001$). We also detected other factors that can contribute on the situations
222 like the number of control patients ($p = 0.032$) (OR: 0.89) [95%CI: 0.81-0.99] and number of
223 control clusters ($p = 0.017$) (OR: 0.85) [95%CI: 0.74-0.97].

224 **DISCUSSION**

225 The overview of our study has undoubtedly affirmed that the number of patients diagnosed with
226 the newly discovered coronavirus has continued to increase every day, affecting many countries
227 all over the world. This virus unfortunately showed a very interactive easily transportation from
228 person to person. Liu et. al. has detected the mean reproductive rate (R_0) of severe acute
229 respiratory syndrome coronavirus 2 (SARS-CoV-2) estimated around 3.28 compared to 3 in
230 SARS^{28,29}. However, some studies have been gone far and estimated R_0 of this new virus to
231 reach above 6 in average indicating the hard situation of the world for the inability to control this
232 emergent disease^{30,31}. Therefore, many countries have put restrictive measures on travelers
233 coming from China to limit the spread of the disease among their populations. In China, the
234 authorities decided to lock down many cities to control the disease which caused people of
235 different nationalities to seek their home return. As a result, the epidemiology and transmission
236 of the disease are vague concerning any possible transmission by asymptomatic patients as the
237 incubation period of COVID-19 is 14 days. On the other hand, a study reported the doubling

238 time of the outbreak inside China to be 7.4 days on January 22, 2020⁶. The mean doubling time
239 we calculated here was every 3.08 ± 0.35 days outside China (**Figure 1**). However, we could not
240 compare both estimates to each other, and other similar outbreaks due to lack of sufficient data of
241 expose time in our sources unlike they had. Therefore, we couldn't either assess R0, besides,
242 further investigations are needed regarding this concern as this rate was likely to be increased
243 with time.

244 Currently in this study we have attempted for more investigation and clustering the
245 epidemiology of the population from outside China who have been related to the outbreak until
246 February 12, 2020. To this date, 446 cases were reported internationally in 24 countries with the
247 highest number of patients among the Singaporean population, and the lowest in Belgium³²,
248 Cambodia³³, Finland³⁴, Nepal³⁵, Sri Lanka³⁶ and Sweden³⁷ which reported only one case each.
249 The huge number of infected patients is due to the Diamond Princess cruise (n = 174) which was
250 locked down on February 3, by the Japanese authorities after COVID-19 was positively
251 confirmed in Hong Kong Chinese man²⁴⁻²⁷. Without these cases, Singapore would have the
252 largest record of on-land confirmed cases of COVID-19 (n = 50)¹⁹ (**Table 1**). The primary
253 transmission (Group A) represented the majority that brought the primary pathogen (n = 168).
254 Moreover, we did more subgrouping of these cases to know where most of cases mostly came
255 from and found the majority of them are Chinese people who recently returned from China (Aa)
256 (n = 159), however, some cases recognized from other sub-endemic countries (Ab) (n = 9) as in
257 Japan³⁸, Singapore³⁹, France⁴⁰, Germany⁴¹, Thailand⁴² and Malaysia⁴³. highlighting that the
258 governments should not only focus on checking people from China, but also, in countries that
259 reported COVID-19 infected cases. In addition, we noticed some of the reported cases had no
260 history of travel to China, where the outbreak took place but had been in close contact with

261 Chinese people, suggesting person to person transmission (F2) which is similar to the (SARS)⁴⁴
262 and (MERS)⁴⁵ outbreaks in 2003 and 2013, respectively (**Table 3, Figure 2**).

263 The primary cases who infected other persons later (F1) were greatest in Thailand (n = 26),
264 Singapore (n = 24), and Japan (n = 19) which is suggestive of the poor tracking the patients
265 entering the country (**Table 4**). In Thailand, a taxi driver was reported to have been infected on
266 January 28, 2020. The patient had no history of travel to China but was in contact with a Chinese
267 tourist which the first case of a person to person transmission in the country⁴⁶. Moreover,
268 transmission with difficulty in detecting the source of infection, and infections with no detectable
269 source (Group C and D) (either not reported or cannot be detected) was presented in some
270 countries. In Australia, UAE and Germany reported 1, 3 and 1 respectively in these two groups,
271 while Asia recorded the highest number of such cases reaching 11 cases in Singapore, 3 in Japan
272 (**Table 4**). These are serious numbers and can be misleading as suggestive of the emergence of
273 the disease in these counties with no transmission from China being reported. However, they
274 were estimated in the early period, so they were not always reflected the current statements as
275 some country may gain the ability to find the links of their cases like Singapore latterly but still
276 give some predictions of future events in other countries like what happened later in Japan and
277 Germany. To note, we try to develop a new way of predictions and rapid judgmental tools of
278 ongoing daily situations report for those countries who care to identify and clarify their present
279 conditions. Therefore, authorities should exert more effort in reporting all cases in an evidence-
280 based manner. The earliest case to be reported outside China was in Thailand on January 13,
281 2020 who had been to China lately²⁰. Besides, the only patient that died from COVID-19 from
282 outside China was reported in Philippine on February 2, 2020²². However, the Death numbers
283 were likely to be increased in the following days because of the continuously increasing numbers

284 of confirmed infected patients.

285 The pathophysiology of this COVID-19 has not powerfully known, but Sohrabi et. al. said that
286 most of the transmission occurred in the symptomatic period with increasing some reporting of
287 asymptomatic transferring cases⁴⁷. Subsequently human to human transmission was reported in
288 Vietnam⁴⁸, Japan⁴⁹ and USA⁵⁰. Some cases are asymptomatic^{12,51,52} due to the 2-week incubation
289 period of the virus which makes it hard to detect these cases, further, possible transmission of the
290 virus to other contacts is easy. In addition, a Vietnamese case was reported with normal clinical
291 findings and mild symptoms⁵³. We couldn't report these findings due to non-adequate
292 information in the majority of cases. Nonetheless, we kept tracked to know about the transferring
293 patterns of this disease in different countries, then we found the direct transmission ratio from
294 Chinese people (F1 to F2) has recorded the highest in the UK (55.6%), Vietnam (44.6%) and
295 Republic of South Korea (24%) while the indirect local ratio (F2 to F3) revealed in South Korea
296 (33.3%) and Vietnam (14.3%) can represent a hazard ratio of outbreak occurrence but still
297 remained non-significant ($p > 0.05$) (**Table 4, Table 5**). However, the impact of unreported
298 Chinese cases in out of control countries was a significantly high risk of the outbreak ($p <$
299 0.001). The time of announcement of cases and the number of control patients or clusters are still
300 risk factors to produce pandemic disease ($p < 0.05$) (**Table 5**). The cluster size didn't show a
301 significant this risk attribution ($p > 0.05$), in spite of that, this assessment has been made in the
302 early stage when the super-spreader factors haven't grown yet. Consequently, healthcare officials
303 must put restrictive measures at all levels for rapid detection of the virus on people coming from
304 China or those countries which became lastly an epicenter of this disease.

305 Eventually, we would like to recommend the diagnostic measures of the COVID-19 to be more
306 developed. Mostly we used RT-PCR techniques according to the WHO recommendations⁵⁴.

307 Samples were effectively positive for the virus from the upper and lower respiratory tract⁶, and
308 stool⁵⁵. Furthermore, the virus was detected in the serum of severely ill patients in China⁵⁶.
309 However, Ai et. al. had another opinion for considering the chest computed tomography (CT) as
310 a primary tool for investigation⁵⁷. He foresaw that the CT scan was much easier and more
311 practical. Another study suggested a combination of both techniques when RT-PCR results were
312 negative but it should be in highly suspicious persons⁵⁸. We also agreed on prevention of the
313 outbreak should include suspected and confirmed cases isolation, rapid monitoring to the
314 contacts with these cases, and preparing the healthcare facilities and training the medical staffs
315 for dealing with such cases. Health education of people who have been in close contact with
316 infected patients for rapid presentation at nosocomial procedures is crucial in controlling the
317 outbreak. Besides, advising susceptible individuals about the importance of hygiene and wearing
318 personal protective equipment (PPE), and staying away from infected or suspected patients is
319 important to prevent person-to-person transmission^{59,60}.

320 While providing more insight into how COVID-19 spread worldwide, highlighting the
321 importance of coordination between clinicians and public health authorities at the local, state,
322 and federal levels, as well as the need for rapid assessment of clinical information related to the
323 care of patients with this emerging infection, it was undoubtedly that there still were several
324 limitations to our study. Incomplete data especially expose time and incubated period of the
325 infected cases, as most of the reports were published as news reports, Ministries of Health press
326 releases with a short description. Furthermore, investigation hence was needed to gather more
327 knowledge about this disease.

328 **CONCLUSION**

329 In this study, we reported the epidemiological features of the COVID-19 outside China. Further

330 investigations for developing proper Identification of SARS-CoV-2 cases through daily national
331 situations reports with keeping contact tracing for unknown patients is crucial to maintain the
332 status of countries on control until finding the best cure for this disease.

333 **LIST OF ABBREVIATIONS**

334 “SARS-CoV” : Severe Acute Respiratory Syndrome Coronavirus.

335 “MERS-CoV” : Middle East Respiratory Syndrome Coronavirus.

336 “SARS-CoV-2” : Severe Acute Respiratory Syndrome Coronavirus 2.

337 “WHO” : World Health Organization.

338 “ARDS” : Acute Respiratory Distress Syndrome

339 “CDC” : Centers For Disease Control And Prevention.

340 “ProMed” : An online news site for international society for infectious diseases.

341 “USA” : United States of America.

342 “UK” : United Kingdom.

343 “UAE” : United Arab Emirates.

344 “PPE”: Personal protective equipment.

345 “NEJM”: The New England Journal of Medicine Journal

346 “JAMA”: The Journal of the American Medical Association

347 **DECLARATIONS**

348 *Ethics approval and consent to participate*

349 Not applicable.

350 *Consent for publication*

351 Not applicable.

352 *Availability of data and materials*

353 All data generated or analysed during this study are included in this published article [and its
354 supplementary information files].

355 ***Funding***

356 No funding resources were gained for this study.

357 ***Competing interests***

358 We declare that the authors had no conflicts of interest while conducting this study.

359 ***Authors' contributions***

360 MDNT was responsible for the idea, AAFA and NTH were responsible for the study design. MDNT,
361 AAFA, LHNM, HDN, KLD and HHL have helped in the collection of dataset. HDN contributed
362 in the drawing of the diagrams of the cases in supplementary material. Data analysis, tables and
363 figures were made by LLTT. MDNT, LLTT, AAFA and NTH interpreted the data results. QLL,
364 LLTT, AAFA and LHNM have contributed in the writing. Final review done by NHT, LLTT and
365 AAFA. The final approval of this version have been made by all participated authors.

366 ***Acknowledgments***

367 None.

368

369

370

371

372 **References:**

- 373 1. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe
374 acute respiratory syndrome. *New England journal of medicine* 2003; 348: 1953-66.
- 375 2. Kuiken T, Fouchier RAM, Schutten M, et al. Newly discovered coronavirus as the primary
376 cause of severe acute respiratory syndrome. *The Lancet* 2003; 362: 263-70.
- 377 3. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with
378 severe acute respiratory syndrome. *New England journal of medicine* 2003; 348: 1967-76.
- 379 4. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a
380 novel coronavirus from a man with pneumonia in Saudi Arabia. *New England Journal of*
381 *Medicine* 2012; 367: 1814-20.
- 382 5. de Groot RJ, Baker SC, Baric RS, et al. Commentary: Middle East respiratory syndrome
383 coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. *Journal of virology*
384 2013; 87: 7790-2.
- 385 6. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel
386 coronavirus–infected pneumonia. *New England Journal of Medicine* 2020.
- 387 7. Xu J, Zhao S, Teng T, et al. Systematic Comparison of Two Animal-to-Human Transmitted
388 Human Coronaviruses: SARS-CoV-2 and SARS-CoV. *Viruses* 2020; 12: 244.
- 389 8. Chinazzi M, Davis JT, Ajelli M, et al. The effect of travel restrictions on the spread of the
390 2019 novel coronavirus (2019-nCoV) outbreak. *medRxiv* 2020.
- 391 9. Bassetti M, Vena A, Roberto Giacobbe D. The Novel Chinese Coronavirus (2019-nCoV)
392 Infections: challenges for fighting the storm. *European Journal of Clinical Investigation* 2020:
393 e13209.

- 394 10. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and
395 pathogenesis. *Journal of medical virology* 2020.
- 396 11. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019
397 novel coronavirus–infected pneumonia in Wuhan, China. *Jama* 2020.
- 398 12. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an
399 asymptomatic contact in Germany. *New England Journal of Medicine* 2020.
- 400 13. Lim J, Jeon S, Shin H-Y, et al. Case of the index patient who caused tertiary transmission of
401 Coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of
402 COVID-19 pneumonia monitored by quantitative RT-PCR. *Journal of Korean Medical Science*
403 2020; 35.
- 404 14. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19.
405 *JAMA* 2020.
- 406 15. Heymann DL, Shindo N. COVID-19: what is next for public health? *The Lancet* 2020..
- 407 16. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is
408 higher compared to SARS coronavirus. *Journal of Travel Medicine* 2020.
- 409 17. Silberg WM, Lundberg GD, Musacchio RA. Assessing, controlling, and assuring the quality
410 of medical information on the Internet: Caveant lector et viewor—Let the reader and viewer
411 beware. *Jama* 1997; 277: 1244-5.
- 412 18. Sugiyama S. *Japan to expand coronavirus testing as 39 more on cruise test positive*. The
413 *Japantimes* 2020, February 12 [cited 2020 Feb 12]; Available from:
414 [https://www.japantimes.co.jp/news/2020/02/12/national/science-health/40-new-coronavirus-](https://www.japantimes.co.jp/news/2020/02/12/national/science-health/40-new-coronavirus-cases-cruise-ship-quarantined-japan/#.XkVSiGgzZPa)
415 [cases-cruise-ship-quarantined-japan/#.XkVSiGgzZPa](https://www.japantimes.co.jp/news/2020/02/12/national/science-health/40-new-coronavirus-cases-cruise-ship-quarantined-japan/#.XkVSiGgzZPa)

- 416 19. MOH. *Six more cases discharged; three new cases of covid-19 infection confirmed.*
417 Singapore: Ministry of Health. 2020, February 12 [cited 2020 Feb 12]; Available from:
418 [https://www.moh.gov.sg/news-highlights/details/six-more-cases-discharged-three-new-cases-of-](https://www.moh.gov.sg/news-highlights/details/six-more-cases-discharged-three-new-cases-of-covid-19-infection-confirmed)
419 [covid-19-infection-confirmed](https://www.moh.gov.sg/news-highlights/details/six-more-cases-discharged-three-new-cases-of-covid-19-infection-confirmed)
- 420 20. Joseph A. *Woman with novel pneumonia virus hospitalized in Thailand — the first case*
421 *outside China.* Statnews. 2020, January 13 [cited 2020 Feb 12]; Available from:
422 [https://www.statnews.com/2020/01/13/woman-with-novel-pneumonia-virus-hospitalized-in-](https://www.statnews.com/2020/01/13/woman-with-novel-pneumonia-virus-hospitalized-in-thailand-the-first-case-outside-china/)
423 [thailand-the-first-case-outside-china/](https://www.statnews.com/2020/01/13/woman-with-novel-pneumonia-virus-hospitalized-in-thailand-the-first-case-outside-china/)
- 424 21. Le C. *Bé gái Vĩnh Phúc 3 tháng tuổi dương tính nCoV.* (in Vietnamese). vnexpress.net. 2020,
425 February 11 [cited 2020 Feb 12]; Available from: [https://baonghean.vn/be-gai-vinh-phuc-3-](https://baonghean.vn/be-gai-vinh-phuc-3-thang-tuoi-duong-tinh-ncov-262253.html)
426 [thang-tuoi-duong-tinh-ncov-262253.html](https://baonghean.vn/be-gai-vinh-phuc-3-thang-tuoi-duong-tinh-ncov-262253.html)
- 427 22. DOH. *Doh reveals more negative 2019-ncov cases; confirms first ncov ard death in ph.*
428 Republic of the Philippines: Department of Health. 2020, February 2 [cited 2020 Feb 12];
429 Available from: [https://www.doh.gov.ph/press-release/DOH-reveals-more-negative-2019-nCoV-](https://www.doh.gov.ph/press-release/DOH-reveals-more-negative-2019-nCoV-cases-confirms-first-nCoV-ARD-death-in-PH)
430 [cases-confirms-first-nCoV-ARD-death-in-PH](https://www.doh.gov.ph/press-release/DOH-reveals-more-negative-2019-nCoV-cases-confirms-first-nCoV-ARD-death-in-PH)
- 431 23. REUTERS. *Thailand reports 1 new case of coronavirus, brings total to 33.* Bangkok Post.
432 2020, February 11 [cited 2020 Feb 12]; Available from:
433 [https://www.bangkokpost.com/thailand/general/1855184/thailand-reports-1-new-case-of-](https://www.bangkokpost.com/thailand/general/1855184/thailand-reports-1-new-case-of-coronavirus-brings-total-to-33)
434 [coronavirus-brings-total-to-33](https://www.bangkokpost.com/thailand/general/1855184/thailand-reports-1-new-case-of-coronavirus-brings-total-to-33)
- 435 24. BBC. *Coronavirus: Ten passengers on cruise ship test positive for virus.* BBC news. 2020,
436 February 5 [cited 2020 Feb 12]; Available from: [https://www.bbc.com/news/world-asia-](https://www.bbc.com/news/world-asia-51381594)
437 [51381594](https://www.bbc.com/news/world-asia-51381594)

- 438 25. MHLW. 横浜港で検疫中のクルーズ船内で確認された新型コロナウイルス感染症に
439 ついて (第5報) . (in Japanese). Japan: Ministry of Health, Labour and Welfare. 2020,
440 February 9 [cited 2020 Feb 12]; Available from:
441 https://www.mhlw.go.jp/stf/newpage_09405.html
- 442 26. MHLW. 新型コロナウイルス感染症の現在の状況と厚生労働省の対応について (令
443 和2年2月13日版) . (in Japanese). Japan: Ministry of Health, Labour and Welfare. 2020,
444 February 13 [cited 2020 Feb 12]; Available from:
445 https://www.mhlw.go.jp/stf/newpage_09490.html
- 446 27. Yonhap. (LEAD) S. Korea confirms 1 more case of novel coronavirus, total now at 28.
447 YONHAB NEWS AGENCY 2020. February 11 [cited 2020 Feb 12]; Available from:
448 <https://en.yna.co.kr/view/AEN20200211002951320>
- 449 28. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is
450 higher compared to SARS coronavirus. *Journal of Travel Medicine* 2020.
- 451 29. Bauch CT, Lloyd-Smith JO, Coffee MP, Galvani AP. Dynamically modeling SARS and
452 other newly emerging respiratory illnesses: past, present, and future. *Epidemiology* 2005: 791-
453 801.
- 454 30. Shen M, Peng Z, Xiao Y, Zhang L. Modelling the epidemic trend of the 2019 novel
455 coronavirus outbreak in China. *bioRxiv* 2020.
- 456 31. Tang B, Wang X, Li Q, et al. Estimation of the transmission risk of the 2019-nCoV and its
457 implication for public health interventions. *Journal of Clinical Medicine* 2020; 9: 462.
- 458 32. Galindo G. *First case of coronavirus confirmed in Belgium*. The Brussels Times. 2020 Feb 4
459 [cited 2020 Feb 12]; Available from: [https://www.brusselstimes.com/all-news/belgium-all-](https://www.brusselstimes.com/all-news/belgium-all-news/93361/first-case-of-coronavirus-confirmed-in-belgium/)
460 [news/93361/first-case-of-coronavirus-confirmed-in-belgium/](https://www.brusselstimes.com/all-news/belgium-all-news/93361/first-case-of-coronavirus-confirmed-in-belgium/)

- 461 33. Thul PC, Johnson K, Evans C. *Cambodia confirms first case of coronavirus -health minister*.
462 Reuters. 2020, January 27 [cited 2020 Feb 12]; Available from:
463 <https://www.reuters.com/article/us-china-health-cambodia/cambodia-confirms-first-case-of->
464 [coronavirus-health-minister-idUSKBN1ZQ1C1](https://www.reuters.com/article/us-china-health-cambodia/cambodia-confirms-first-case-of-coronavirus-health-minister-idUSKBN1ZQ1C1)
- 465 34. YLE. *Finland's first coronavirus case confirmed in Lapland*. Yle news. 2020, January 29
466 [cited 2020 Feb 12]; Available from:
467 https://yle.fi/uutiset/osasto/news/finlands_first_coronavirus_case_confirmed_in_lapland/111828
468 55
- 469 35. Bastola A, Sah R, Rodriguez-Morales AJ, et al. The first 2019 novel coronavirus case in
470 Nepal. *The Lancet Infectious Diseases* 2020; 20: 279-80.
- 471 36. ColomboPage. *First patient with coronavirus reported in Sri Lanka*. ColomboPage. 2020,
472 January 27 [cited 2020 Feb 12]; Available from:
473 http://www.colombopage.com/archive_20A/Jan27_1580144354CH.php
- 474 37. TheLocal.se. *First case of coronavirus confirmed in Sweden*. TheLocal.se. 2020, January 31
475 [cited 2020 Feb 12]; Available from: <https://www.thelocal.se/20200131/first-case-of->
476 [coronavirus-confirmed-in-jonkoping-sweden/amp](https://www.thelocal.se/20200131/first-case-of-coronavirus-confirmed-in-jonkoping-sweden/amp)
- 477 38. Yonhab. *신종코로나 국내 12 번째 환자... 일본환자 접촉 49세 중국남성(종합2보)*. (In
478 Korean). Republic of South Korea: Yonhap News. 2020, February 1 [cited 2020 Feb 12];
479 Available from: <https://www.yna.co.kr/view/AKR20200201023653017>
- 480 39. Yonhab. *(6th LD) 3 more virus cases bring S. Korea's total to 19, two confirmed after trip to*
481 *Singapore*. Republic of South Korea: Yonhap News Agency. 2020, February 5 [cited 2020 Feb
482 12]; Available from: <https://en.yna.co.kr/view/AEN20200205002356320>
- 483 40. Jones J, Richardson A, Potter M. *Spanish authorities confirm Briton is country's second*

- 484 *coronavirus case*. Reuters. 2020, February 9 [cited 2020 Feb 12]; Available from:
485 <https://www.reuters.com/article/us-china-health-spain-idUSKBN20309T>
- 486 41. Linde P. *Sanidad confirma en La Gomera el primer caso de coronavirus en España*. (in
487 Spanish). Madrid: EL PAIS. 2020, January 31 [cited 2020 Feb 12]; Available from:
488 https://elpais.com/sociedad/2020/01/31/actualidad/1580509404_469734.html
- 489 42. Choon CM. *South Korean woman who returned home from Bangkok diagnosed with the*
490 *coronavirus South Korea*. THE STRAITS TIMES. 2020, February 4 [cited 2020 Feb 12];
491 Available from: [https://www.straitstimes.com/asia/east-asia/coronavirus-south-korean-woman-](https://www.straitstimes.com/asia/east-asia/coronavirus-south-korean-woman-travelling-home-from-thailand-tests-positive-for-virus)
492 [travelling-home-from-thailand-tests-positive-for-virus](https://www.straitstimes.com/asia/east-asia/coronavirus-south-korean-woman-travelling-home-from-thailand-tests-positive-for-virus)
- 493 43. MOH. *Four more cases discharged; three new confirmed cases of novel coronavirus*
494 *infection*. Singapore: Ministry of Health. 2020, February 9 [cited 2020 Feb 12]; Available from:
495 [https://www.moh.gov.sg/news-highlights/details/four-more-cases-discharged-three-new-](https://www.moh.gov.sg/news-highlights/details/four-more-cases-discharged-three-new-confirmed-cases-of-novel-coronavirus-infection)
496 [confirmed-cases-of-novel-coronavirus-infection](https://www.moh.gov.sg/news-highlights/details/four-more-cases-discharged-three-new-confirmed-cases-of-novel-coronavirus-infection)
- 497 44. Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory
498 syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. *The Lancet*
499 2003; 362: 1353-8.
- 500 45. Darling ND, Poss DE, Schoelen MP, Metcalf-Kelly M, Hill SE, Harris S. Retrospective,
501 epidemiological cluster analysis of the Middle East respiratory syndrome coronavirus (MERS-
502 CoV) epidemic using open source data. *Epidemiology & Infection* 2017; 145: 3106-14.
- 503 46. Pongpirul WA, Pongpirul K, Ratnarathon AC, Prasithsirikul W. Journey of a Thai Taxi
504 Driver and Novel Coronavirus. *New England Journal of Medicine* 2020.

- 505 47. Sohrabi C, Alsafi Z, O'Neill N, et al. World Health Organization declares global emergency:
506 A review of the 2019 novel coronavirus (COVID-19). *International Journal of Surgery* 2020; 76:
507 71-6.
- 508 48. Phan LT, Nguyen TV, Luong QC, et al. Importation and human-to-human transmission of a
509 novel coronavirus in Vietnam. *New England Journal of Medicine* 2020; 382: 872-4.
- 510 49. Kyodo. *Japan reports first domestic transmission of coronavirus Japan*. The Japantimes.
511 2020, January 28 [cited 2020 Feb 12]; Available from:
512 [https://www.japantimes.co.jp/news/2020/01/28/national/japan-first-domestic-transmission-](https://www.japantimes.co.jp/news/2020/01/28/national/japan-first-domestic-transmission-coronavirus/#XkC_4KTd_IV)
513 [coronavirus/#XkC_4KTd_IV](https://www.japantimes.co.jp/news/2020/01/28/national/japan-first-domestic-transmission-coronavirus/#XkC_4KTd_IV)
- 514 50. Lovelace B. *CDC confirms second US case of coronavirus and is monitoring dozens of other*
515 *potential cases*. CNBC. 2020, January 24 [cited 2020 Feb 12]; Available from:
516 [https://www.cnbc.com/2020/01/24/cdc-confirms-second-us-case-of-coronavirus-chicago-](https://www.cnbc.com/2020/01/24/cdc-confirms-second-us-case-of-coronavirus-chicago-resident-diagnosed.html)
517 [resident-diagnosed.html](https://www.cnbc.com/2020/01/24/cdc-confirms-second-us-case-of-coronavirus-chicago-resident-diagnosed.html)
- 518 51. MHLW. *新型コロナウイルス感染症の現在の状況と厚生労働省の対応について（令*
519 *和2年2月10日版）*. (in Japanese). Japan: Ministry of Health, Labour and Welfare. 2020,
520 February 10 [cited 2020 Feb 12]; Available from:
521 https://www.mhlw.go.jp/stf/newpage_09418.html
- 522 52. Duncan G, Gautam S. *Coronavirus: UAE records first case*. TheNational.ae. 2020 January
523 29 [cited 2020 Feb 12]; Available from: [https://www.thenational.ae/uae/health/coronavirus-uae-](https://www.thenational.ae/uae/health/coronavirus-uae-records-first-case-1.971253)
524 [records-first-case-1.971253](https://www.thenational.ae/uae/health/coronavirus-uae-records-first-case-1.971253)
- 525 53. Giang HTN, Shah J, Hung TH, Reda A, Truong LN, Huy NT. The first Vietnamese case of
526 COVID-19 acquired from China. *The Lancet Infectious Diseases* 2020.

- 527 54. WHO. *Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-*
528 *nCoV in humans*. 2020 [cited 2020 Feb 17]; Available from:
529 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance)
530 [guidance](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance)
- 531 55. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United
532 States. *New England Journal of Medicine* 2020.
- 533 56. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
534 coronavirus in Wuhan, China. *The Lancet* 2020; 395: 497-506.
- 535 57. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus
536 disease 2019 (COVID-19) in China: A report of 1014 cases. *Radiology* 2020: 200642.
- 537 58. Huang P, Liu T, Huang L, et al. Use of chest CT in combination with negative RT-PCR
538 assay for the 2019 novel coronavirus but high clinical suspicion. *Radiology* 2020: 200330.
- 539 59. Baharoon S, Memish ZA. MERS-CoV as an emerging respiratory illness: A review of
540 prevention methods. *Travel medicine and infectious disease* 2019: 101520.
- 541 60. Pavli A, Tsiodras S, Maltezou HC. Middle East respiratory syndrome coronavirus (MERS-
542 CoV): prevention in travelers. *Travel medicine and infectious disease* 2014; 12: 602-8.
543

544 **FIGURE LEGENDS**

545 **Figure 1:** The total number of infected patients globally since the first case was reported until

546 February 12, 2020

547 **Legend:** Doubling time 3.08 ± 0.35 days

548 **Figure 2.** The transmission of COVID-19 from China to other countries

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567 **Table 1: Summary of infected cases around the world outside China (n = 446)**

Country	n (%)	Announcement	
		First case	Last case
Australia	15 (3.4)	25.01.2020	06.02.2020
Belgium	1 (0.2)	01.02.2020	01.02.2020
Cambodia	1 (0.2)	27.01.2020	27.01.2020
Canada	7 (1.6)	27.01.2020	07.02.2020
Finland	1 (0.2)	29.01.2020	29.01.2020
France	11 (2.5)	25.01.2020	08.02.2020
Germany	16 (3.6)	27.01.2020	12.02.2020
India	3 (0.7)	30.01.2020	03.02.2020
Italy	3 (0.7)	31.01.2020	07.02.2020
Japan	29 (6.5)	15.01.2020	11.02.2020
South Korea	28 (6.3)	23.01.2020	11.02.2020
Malaysia	18 (4)	24.01.2020	10.02.2020
Nepal	1 (0.2)	25.01.2020	25.01.2020
Philippine	3 (0.7)	30.01.2020	05.02.2020
Russia	2 (0.4)	31.01.2020	31.01.2020
Singapore	50 (11.2)	23.01.2020	12.02.2020
Spain	2 (0.4)	01.02.2020	09.02.2020
Sri Lanka	1 (0.2)	28.01.2020	28.01.2020
Sweden	1 (0.2)	31.01.2020	31.01.2020
Thailand	33 (7.4)	13.01.2020	11.02.2020
UAE	8 (1.8)	29.01.2020	10.02.2020
UK	9 (2)	31.01.2020	12.02.2020
US	14 (3.1)	23.01.2020	12.02.2020
Vietnam	15 (3.4)	22.01.2020	11.02.2020
International conveyance (Diamond Princess)	174 (39)	07.02.2020	11.02.2020

Total	446	13.01.2020	12.02.2020
568			
569			
570			
571			
572			
573			
574			
575			
576			
577			
578			
579			
580			
581			
582			
583			
584			
585			
586			
587			
588			
589			
590			

591 **Table 2: Demographic features of the infected cases (n = 446)**

Patient characteristics	n (%)	Valid %	Median (IQR)
Sex			
Female	97 (21.7)	43.1	
Male	128 (28.7)	56.9	
No report	221 (49.6)	-	
Age (years)			42 (32-56)
Report	164 (36.8)		
No report	282 (63.2)		
Survival/Death			
Dead	1 (0.2)		
Survived	445 (99.8)		

592

593

594

595

596

597

598

599

600

601

602

603 **Table 3: Demographic features of the transmission clusters (n = 214)**

Cluster characteristics		n (%)
Cluster type		
Group Aa	1	159 (74.3)
	2	9 (4.2)
	3	2 (0.9)
Group Ab	1	9 (4.2)
	2	3 (1.4)
	3	0 (0)
Group B	2	6 (2.8)
	3	3 (1.4)
Group C	0	9 (4.2)
	1	1 (0.5)
Group D	0	13 (6.1)
	1	0 (0)
Cluster size		
	1	192 (89.7)
	2	12 (5.6)
	3	3 (1.4)
	6	4 (1.9)
	9	1 (0.5)
	13	1 (0.5)
	175	1 (0.5)

Legend:

Source identified clusters (Primary pathogen was identified)

Aa: Reported primary pathogen came from China

Ab: Reported primary pathogen came from other endemic foreign countries

B: Primary pathogen were Chinese tourists without reporting as a case in the country.

1: Only F1 patient

2: F1 and F2 patients

3: F1, F2 and F3 patients

Unknown source clusters (Primary pathogen was not identified/reported)

C: Cluster related to a local area.

D: No information

0: Only F_n patients (patients related to area clusters)

1: F_n and F_{n+1} patients

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626 **Table 4: Epidemiology of the transmission clusters across countries.**

Country	Estimated time of epidemic circulating (days)	Group A						Group B			Group C			Group D		
		Number of F1 patients	Transmission ratio (%)			Cluster size	Total number of patients	Cluster characteristics		Total number of patients	Cluster characteristics		Total number of patients	Cluster characteristics		Total number of patients
			From F1 to F2 patients	From F2 to F3 patients	From F1 to F3 patients			Number of clusters	Cluster size		Number of clusters	Cluster size		Number of clusters	Cluster size	
n	n	%	%	%	mean (range)	n	n	mean (range)	n	n	mean (range)	n	n	mean (range)	n	
Australia	19	14	0	-	0	1	14	0	-	-	0	-	-	1	1	1
Belgium	12	1	0	-	0	1	1	0	-	-	0	-	-	0	-	-
Cambodia	17	1	0	-	0	1	1	0	-	-	0	-	-	0	-	-
Canada	17	6	14.3	0	14.3	1 (1-2)	7	0	-	-	0	-	-	0	-	-
Finland	14	1	0	-	0	1	1	0	-	-	0	-	-	0	-	-
France	19	4	20	0	20	1 (1-2)	5	1	6	6	0	-	-	0	-	-
Germany	17	2	0	-	0	1	2	1	1	1	1	13	13	0	-	-
India	14	3	0	-	0	1	3	0	-	-	0	-	-	0	-	-
Italy	13	3	0	-	0	1	3	0	-	-	0	-	-	0	-	-
Japan	29	21	8.7	0	8.7	1 (1-2)	23	2	1	2	1	1	1	2	1	2
South Korea	21	19	24	33.3	32.1	1 (1-6)	28	0	-	-	0	-	-	0	-	-
Malaysia	20	17	5.6	0	5.6	1 (1-2)	18	0	-	-	0	-	-	0	-	-
Nepal	19	1	0	-	0	1	1	0	-	-	0	-	-	0	-	-
Philippines	14	3	0	-	0	1	3	0	-	-	0	-	-	0	-	-
Russia	13	2	0	-	0	1	2	0	-	-	0	-	-	0	-	-
Singapore	21	24	0	-	0	1	24	2	5 (1-9)	10	6	1.83 (1-3)	11	5	1	5
Spain	12	2	0	-	0	1	2	0	-	-	0	-	-	0	-	-
Sri Lanka	16	1	0	-	0	1	1	0	-	-	0	-	-	0	-	-
Sweden	13	1	0	-	0	1	1	0	-	-	0	-	-	0	-	-
Thailand	31	26	0	-	0	1	26	2	1.5 (1-2)	3	2	1	2	2	1	2
UAE	15	5	0	-	0	1	5	0	-	-	0	-	-	3	1	3
UK	13	4	55.6	0	55.6	2 (1-6)	9	0	-	-	0	-	-	0	-	-

US	21	13	7.1	0	7.1	$\frac{1}{(1-2)}$	14	0	-	-	0	-	-	0	-	-
Vietnam	22	8	42.9	14.3	46.7	$\frac{2}{(1-6)}$	15	0	-	-	0	-	-	0	-	-

Transmission ratio:

From F1 to F2: $F2/(F1+F2)$

From F2 to F3: $F3/(F2+F3)$

From F1 to F3: $(F2+F3)/(F1+F2+F3)$

627

628

629

630

631

632

633

634

635

636

637

Table 5: Factors associated with occurrence of an infected individual with unknown source (N = 24)

Country characteristics	Occurrence of event		Logistic regression analysis	
	Median (IQR) or n(%)		OR (95%CI)	p value
	No (n = 18)	Yes (n = 6)		
Estimated time of epidemic circulating (days)	15 (13-19)	20 (17-29)	0.76 (0.58-0.99)	0.044
Unreported information of Chinese tourists				<0.001^(*)
Yes	0 (0)	4 (66.7)		
No	18 (100)	2 (33.3)		
Number of identified infected source clusters	3 (1-6)	19 (5-26)	0.85 (0.74-0.97)	0.017
Number of identified infected source patients	3 (1-11)	20 (5-29)	0.89 (0.81-0.99)	0.032
Highest size of an identified infected	1 (1-1)	2 (1-2)	0.93 (0.63-1.37)	0.718

source cluster				
Transmission to F2			0.32 (0.05-2.22)	0.248
Yes	7 (38.9)	4 (66.7)		
No	11 (61.1)	2 (33.3)		
Transmission to F3			1.00 (0.08-11.93)	1.000
Yes	3 (16.7)	1 (16.7)		
No	15 (83.3)	5 (83.3)		
(*) : Fisher exact test were performed instead of logistic regression				



